Pfizer Inc. (NYSE:PFE) – Investment analysts at Jefferies Group lowered their FY2017 earnings per share estimates for shares of Pfizer in a research report issued on Thursday. Jefferies Group analyst J. Holford now expects that the brokerage will post earnings per share of $2.67 for the year, down from their previous estimate of $2.71. Jefferies Group currently has a “Hold” rating and a $36.00 price target on the stock. Jefferies Group also issued estimates for Pfizer’s FY2018 earnings at $2.92 EPS, FY2019 earnings at $2.87 EPS and FY2020 earnings at $3.08 EPS.
Several other equities analysts have also commented on the stock. Sanford C. Bernstein set a $36.00 target price on shares of Pfizer and gave the company a “buy” rating in a report on Wednesday. BMO Capital Markets reaffirmed an “outperform” rating and set a $40.00 target price on shares of Pfizer in a report on Tuesday. Vetr raised shares of Pfizer from a “buy” rating to a “strong-buy” rating and set a $37.42 target price on the stock in a report on Monday. Argus reaffirmed a “buy” rating and set a $39.00 target price on shares of Pfizer in a report on Tuesday, October 4th. Finally, Bank of America Corp. reaffirmed a “buy” rating and set a $40.00 target price on shares of Pfizer in a report on Tuesday, September 27th. Eleven research analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $38.55.
Pfizer (NYSE:PFE) traded down 0.43% during midday trading on Monday, reaching $32.55. 4,429,111 shares of the company’s stock traded hands. The stock has a market cap of $197.44 billion, a P/E ratio of 28.86 and a beta of 0.86. The company’s 50-day moving average price is $33.89 and its 200-day moving average price is $34.37. Pfizer has a 52-week low of $28.25 and a 52-week high of $37.39.
Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 earnings per share for the quarter, beating the consensus estimate of $0.62 by $0.02. Pfizer had a net margin of 14.88% and a return on equity of 23.37%. The firm earned $13.10 billion during the quarter, compared to the consensus estimate of $13.01 billion. During the same period in the previous year, the firm posted $0.56 earnings per share. The business’s revenue was up 10.9% compared to the same quarter last year.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 1st. Shareholders of record on Friday, November 11th will be paid a dividend of $0.30 per share. The ex-dividend date of this dividend is Tuesday, November 8th. This represents a $1.20 dividend on an annualized basis and a yield of 3.67%. Pfizer’s dividend payout ratio is currently 95.24%.
Hedge funds have recently added to or reduced their stakes in the stock. Nelson Roberts Investment Advisors LLC raised its stake in shares of Pfizer by 6.7% in the second quarter. Nelson Roberts Investment Advisors LLC now owns 2,999 shares of the biopharmaceutical company’s stock worth $106,000 after buying an additional 189 shares in the last quarter. Stelac Advisory Services LLC bought a new stake in shares of Pfizer during the second quarter worth approximately $110,000. Tuttle Tactical Management LLC bought a new stake in shares of Pfizer during the second quarter worth approximately $117,000. Gierl Augustine Investment Management Inc raised its stake in shares of Pfizer by 5.8% in the third quarter. Gierl Augustine Investment Management Inc now owns 3,718 shares of the biopharmaceutical company’s stock worth $126,000 after buying an additional 205 shares in the last quarter. Finally, Delphi Private Advisors LLC raised its stake in shares of Pfizer by 1.2% in the second quarter. Delphi Private Advisors LLC now owns 4,007 shares of the biopharmaceutical company’s stock worth $141,000 after buying an additional 47 shares in the last quarter. Institutional investors and hedge funds own 69.66% of the company’s stock.
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.